All In Biotech

Drug Trial Radar · NCT07029828

A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

A LONG-TERM, DOUBLE-BLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Sep 10, 2025

Primary completion

Jun 26, 2030

Study completion Jun 26, 2030

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jun 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to learn about long-term safety and long-term effects of the study medicine (called ritlecitinib) for the potential treatment of severe alopecia areata, a condition that causes hair loss. This study is seeking participants who have: * previously completed one of Pfizer's pediatric studies for Alopecia Areata (B7981027 or B7981031). * at least 50% scalp hair loss due to alopecia areata (for participants enrolling from the study B7981031). * received varicella vaccination (2 doses) or have been infected by varicella zoster virus before based on blood test reports. All participants in this study will receive the study medicine (ritlecitinib). Participants who received ritlecitinib higher or lower doses in the parent Study B7981027 will continue receiving the same ritlecitinib dose in this trial. Participants who received placebo in the parent Study B7981027 and all participants from parent Study B7981031 will receive either higher or lower dose of ritlecitinib in this trial. The study medicine is a capsule that is taken by mouth. It is taken 1 time each day at home. The study will help see if ritlecitinib is safe and effective. Participants will take part in this study for a duration of up to 3 years (36 months). During this time, they will have 17 study visits at the study clinic. The study team will also call participants once a month over the phone.

Conditions

  • Severe Alopecia Areata

Interventions

  • Ritlecitinib higher doseDrug

    Study intervention will be provided as oral capsules centrally by the sponsor in HDPE bottles.

  • Ritlecitinib lower doseDrug

    Study intervention will be provided as oral capsules centrally by the sponsor in HDPE bottles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (AEs).Time frame: From the time participant signs informed consent/assent, through and including a minimum of 28 calendar days after the last administration of the study intervention (up to approximately 3 years).
  2. Incidence of Serious Adverse Events (SAEs) and AEs leading to permanent discontinuation from the study.Time frame: From the time participant signs informed consent/assent, through and including a minimum of 28 calendar days after the last administration of the study intervention (up to approximately 3 years).

Locations

69 sites in 9 countries. Site status is shown where the registry gives one.

  • University of California~ Irvine

    Irvine, California · Recruiting

  • Southern California Clinical Research

    Santa Ana, California · Recruiting

  • Children's Hospital Colorado

    Aurora, Colorado · Recruiting

  • Children's National Hospital

    Washington D.C., District of Columbia · Recruiting

  • Pediatric Skin Research

    Miami, Florida · Recruiting

  • Endeavor Health Clinical Operations

    Skokie, Illinois · Recruiting

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana · Recruiting

  • Kindred Hair and Skin Center

    Marriottsville, Maryland · Recruiting

  • Michigan Dermatology Institute

    Waterford, Michigan · Recruiting

  • Skin Specialists, PC dba Schlessinger MD

    Omaha, Nebraska · Recruiting

  • University of New Mexico Health Sciences Center

    Albuquerque, New Mexico · Recruiting

  • University of New Mexico-IDS Pharmacy

    Albuquerque, New Mexico · Recruiting

  • Northwest Dermatology Institute

    Portland, Oregon · Recruiting

  • Penn State Health Milton S. Hershey Medical Center

    Hershey, Pennsylvania · Recruiting

  • Medical University of South Carolina - South Carolina Translational Research Nexus Clinic

    Charleston, South Carolina · Recruiting

  • Dell Children's Medical Center

    Austin, Texas · Recruiting

  • Driscoll Children's Hospital

    Corpus Christi, Texas · Recruiting

  • 3A Research

    El Paso, Texas · Recruiting

  • Austin Institute for Clinical Research

    Pflugerville, Texas · Recruiting

  • Texas Dermatology and Laser Specialists

    San Antonio, Texas · Recruiting

  • Children's Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Children's hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Tongren Hospital affiliated to Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Tongren Hospital affiliated to Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Hunan Children's Hospital

    Changsha, Hunan, China · Recruiting

  • Xiangya Hospital Central South University

    Changsha, Hunan, China · Recruiting

  • Huashan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Chengdu Women and Children Center Hospital

    Chengdu, Sichuan, China · Recruiting

  • The First People's Hospital of Hangzhou

    Hangzhou, Zhejiang, China · Recruiting

  • Hangzhou Third Hospital

    Hangzhou, Zhejiang, China · Recruiting

  • Fakultní Nemocnice Brno

    Brno, Czechia · Recruiting

  • Fakultni Nemocnice Plzen

    Pilsen, Czechia · Recruiting

  • Prof. MUDr. Petr Arenberger, DrSc., MBA

    Prague, Czechia · Recruiting

  • Fakultni nemocnice Bulovka

    Praha 8 - Libeň, Czechia · Recruiting

  • Hospices Civils de Lyon - CIC - Hopital Louis Pradel

    Bron, France · Recruiting

  • Hospices Civils de Lyon - Hopital Femme Mere Enfant

    Bron, France · Recruiting

  • CHU de Dijon Bourgogne

    Dijon, France · Recruiting

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.